|
V. Peters*, T. Singh, K. Dominguez, M. L. Lindegren, and P. Thomas.
New York City Dept. of Health, and CDC, Atlanta, GA.
Background:The objective of this work is to describe trends in prenatal antiretroviral therapies (ARTS) and in Cesarean section (C-S) deliveries for perinatal HIV prevention in NYC.
Methods:Data on ARTS, infant HIV infection status, and mode of delivery were abstracted from infant records of HIV-exposed infants at 22 sites that participate in Pediatric Spectrum of HIV Disease and/or pediatric HIV Surveillance in NYC. Data are available for 2,284 births from 1/96 through 12/99 (68% of NYC HIV exposed births, NYS Comprehensive Newborn Screening Program). HIV status is examined for 1,430 births from 1/96 through 6/99.
Results:Among 1,600 mothers with known prenatal (PN) care, 80% had a PN HIV diagnosis; 76% were prescribed PN ART: from 1996 through 1999, PN zidovudine (ZDV) use alone decreased from 69% to 33% and PN ZDV use with other ARTS increased from 3% to 44%.
From 1996 through 1999, C-S increased from 20% to 39%. In 1999, 90 women had C-S for HIV prevention and PN ART: 3% of infants were infected (48% were indeterminate).
Conclusions:From 1996 through 1999, there was an increase in the use of PN combination ARTS and elective C-S deliveries for perinatal HIV prevention. The lowest perinatal HIV transmission rates are associated with PN combination ARTs.
© 8th Conference on Retroviruses and Opportunistic Infections